Table 2.
Mixed-model analysis of variance results on changes in participant symptomology.
| Characteristics | n | Score mean (SD) | Min-maxa | P value | |
| Y-BOCSb | — | — | — | .04 | |
|
|
Baseline | 10 | 23.3 (6.5) | 15 (36) | — |
|
|
Posttreatment | 10 | 17.1 (9.9) | 2 (34) | — |
|
|
3-month | 10 | 19.4 (7.5) | 9 (32) | — |
|
|
6-month | 10 | 18.6 (8.1) | 7 (32) | — |
|
|
12-month | 10 | 19.2 (8.4) | 8 (29) | — |
| PDSSc | — | — | — | .01 | |
|
|
Baseline | 7 | 8.9 (3.8) | 5 (16) | — |
|
|
Posttreatment | 7 | 5.3 (6.7) | 0 (19) | — |
|
|
3-month | 7 | 5.4 (4.9) | 2 (13) | — |
|
|
6-month | 6 | 4.5(6.1) | 0 (16) | — |
|
|
12-month | 6 | 4.5 (3.6) | 0 (10) | — |
| LSASd | — | — | — | .01 | |
|
|
Baseline | 8 | 96.6 (27.3) | 53 (132) | — |
|
|
Posttreatment | 8 | 57.4 (34.7) | 21 (128) | — |
|
|
3-month | 8 | 62.6 (34.4) | 20 (112) | — |
|
|
6-month | 6 | 57.3 (31.9) | 7 (85) | — |
|
|
12-month | 7 | 65.7 (43.8) | 10 (118) | — |
| PHQ-9e | — | — | — | .007 | |
|
|
Baseline | 25 | 8.8 (6.2) | 0 (23) | — |
|
|
Posttreatment | 25 | 6.8 (7.0) | 0 (22) | — |
|
|
3-month | 25 | 7.2 (5.8) | 0 (24) | — |
|
|
6-month | 22 | 6.6 (6.1) | 0 (19) | — |
|
|
12-month | 23 | 6.1 (5.7) | 0 (20) | — |
| GAD-7f | — | — | — | .009 | |
|
|
Baseline | 25 | 8.8 (5.3) | 0 (20) | — |
|
|
Posttreatment | 25 | 5.5 (5.1) | 0 (16) | — |
|
|
3-month | 25 | 7.2 (4.6) | 0 (19) | — |
|
|
6-month | 25 | 6.3 (5.0) | 0 (21) | — |
|
|
12-month | 23 | 5.8 (4.5) | 0 (14) | — |
amin-max: minimum to maximum.
bY-BOCS: Yale-Brown Obsessive-Compulsive Scale.
cPDSS: Panic Disorder Severity Scale.
dLSAS: Livobitz Social Anxiety Scale.
ePHQ-9: Patient Health Questionnaire–9.
fGAD-7: Generalized Anxiety Disorder–7.